PHIOGEN, INC

HOUSTON, TX, 77030

Unclaimed

Small Business

Subcontracting experience

1 record from government sources. Past participation is not evidence of current teaming interest.

Role	Agency	Description	Vehicle	Obligated	Action date	Period
Subcontractor	Department of Health and Human Services	PHIOGEN’S MISSION IS TO EXPLORE THE MICROBIAL WORLD FOR BACTERIOPHAGES WITH NOVEL THERAPEUTIC POTENTIAL. OUR PRELIMINARY DATA HIGHLIGHT A BREAKTHROUGH DISCOVERY WITH A FIRST-IN-CLASS SOLUTION OF DUAL ACTION THERAPEUTICS: A SERIES OF PHAGES THAT NOT ONLY DEMONSTRATE STRONG EFFICACY AGAINST ANTIMICROBIAL-RESISTANT (AMR) BACTERIA BUT ALSO CONFERRED LONG-TERM PROTECTION AGAINST REINFECTION WITHOUT REQUIRING A SECOND TREATMENT. THE LEADING HYPOTHESIS IS THAT CERTAIN PHAGES, BY UNIQUELY LYSING OUR BACTERIAL TARGETS, ELICIT A PROINFLAMMATORY RESPONSE THAT SUBSEQUENTLY ACTIVATES ADAPTIVE IMMUNITY AGAINST SPECIFIC BACTERIAL ANTIGENS. THIS IMMUNE PRIMING MAY PREVENT FUTURE INFECTIONS. TRADITIONALLY, MEDICAL INTERVENTIONS HAVE BEEN EITHER PROACTIVE (E.G., VACCINES) OR REACTIVE (E.G., THERAPIES). THE DISCOVERY AND INVESTIGATION PRESENTED HERE IS HIGHLY INNOVATIVE AND SIGNIFICANT, AS WE SUGGEST A NEW CLASS OF DUAL ACTION THERAPEUTICS, ONES THAT ACTS BOTH AS A TREATMENT AND INDUCES A PROTECTIVE RESPONSE AGAINST A SECOND INFECTION. GLOBALLY, SIX BACTERIAL SPECIES ARE RESPONSIBLE FOR THE MAJORITY OF THE 5 MILLION ANNUAL DEATHS DUE TO ANTIBIOTIC RESISTANCE, THE SO-CALLED "ESKAPE" SPECIES. WITH THE BACKING OF VARIOUS FUNDERS AND COLLABORATORS, PHIOGEN HAS ASSEMBLED A COLLECTION OF DOZENS OF NOVEL PHAGES TARGETING THESE HIGH-PRIORITY AMR PATHOGENS. FOR THESE PATHOGENS, THERAPEUTIC OPTIONS ARE SCARCE, AND NO VACCINES CURRENTLY EXIST. DEMONSTRATING THAT SOME OF THESE PHAGES POSSESS DUAL THERAPY-IMMUNIZATION PROPERTIES WOULD REPRESENT A PARADIGM SHIFT IN INFECTIOUS DISEASE TREATMENT AND PREVENTION. KC4094 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending	—	$439,033	Jul 24, 2025	— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.